Revvity, Inc.(RVTY) Stock Research - Grey Stern Research
Loading...

Revvity, Inc. (RVTY) Stock Analysis

$107.34 (-0.02%)

RVTY Financial Performance


Use the table below to view Revvity, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $107.34 -
52 Week Low $97.32 -
52 Week High $129.50 -
Market Cap $12.9 Billion 1/1
Gross Margin 57% 1/1
Profit Margin 13% 1/1
EBITDA margin 16% 1/1
Q4 - 2024 Revenue $729.4 Million 1/1
Q4 - 2024 Earnings $94.6 Million 1/1
Q4 - 2024 Free Cash Flow $149.8 Million 1/1
Trailing 4 Quarters Revenue $2.7 Billion 1/1
Trailing 4 Quarters Earnings $311.3 Million 1/1
Quarterly Earnings Growth 49% 1/1
Annual Earnings Growth 238% 1/1
Quarterly Revenue Growth 5% 1/1
Annual Revenue Growth 0% 1/1
Cash On Hand $1.2 Billion 1/1
Short Term Debt $242,000 1/1
Long Term Debt $3.3 Billion 1/1

Revvity, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Revvity, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 41.43 1/1
PS 4.75 1/1
PB 1.68 1/1
PC 11.09 1/1
Liabilities to Equity 0.62 1/1
ROA 0.03 1/1
ROE 0.04 1/1
Current Ratio 2.62 1/1
Quick Ratio 0.25 1/1
Long Term Debt to Equity 0.43 1/1
Debt to Equity 0.43 1/1
Burn Rate 31.03 1/1
Cash to Cap 0.09 1/1
CCR 1.58 1/1
EV to EBITDA 126.61 1/1
EV to Revenue 5.54 1/1

Company Details

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

CEO: Dr. Prahlad R. Singh Ph.D.

Website: https://www.perkinelmer.com

Address: 940 Winter Street Waltham, MA

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Revvity, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Revvity, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RVTY Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 729.4 Million $94.6 Million
Q3 2024 $ 641.7 Million $115.3 Million
Q2 2024 $ 691.7 Million $72.6 Million
Q1 2024 $ 649.9 Million $28.7 Million
Q4 2023 $ 695.9 Million $63.6 Million
Q3 2023 $ 670.7 Million $9.5 Million
Q2 2023 $ 709.1 Million $35.6 Million
Q1 2023 $ 674.9 Million $24.8 Million

View All

RVTY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $1.2 Billion $12.4 Billion $3.3 Billion $7.7 Billion
Q3 2024 $1.2 Billion $12.8 Billion $3.3 Billion $7.9 Billion
Q2 2024 $1.2 Billion $13.4 Billion $4.0 Billion $7.9 Billion
Q1 2024 $999.5 Million $13.4 Billion $4.0 Billion $7.8 Billion
Q4 2023 $914.4 Million $13.6 Billion $4.0 Billion $7.9 Billion
Q3 2023 $1.1 Billion $13.4 Billion $4.0 Billion $7.7 Billion
Q2 2023 $1.3 Billion $14.2 Billion $4.5 Billion $7.9 Billion
Q1 2023 $2.3 Billion $14.6 Billion $4.5 Billion $8.0 Billion

View All

RVTY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $149.8 Million -$24.5 Million -$66.4 Million
Q3 2024 $271.7 Million -$15.1 Million -$569.3 Million
Q2 2024 $136.6 Million -$22.0 Million $251.3 Million
Q1 2024 $129.7 Million -$17.8 Million $85.1 Million
Q4 2023 $172.5 Million -$24.1 Million -$222.3 Million
Q3 2023 -$55.8 Million -$22.4 Million -$195.4 Million
Q2 2023 -$149.3 Million -$13.9 Million -$935.2 Million
Q1 2023 $42.5 Million -$20.9 Million $1.8 Billion

View All